AngioDynamics Surpasses Expectations with $79.4M Sales and Break-Even EPS

Written by Emily J. Thompson, Senior Investment Analyst

ANGO-2.1%

ALMS-1.41%

CYCN0%

Source: Benzinga

Updated: Jan 06 2026

0mins

Source: Benzinga

Earnings Beat: AngioDynamics reported an adjusted EPS of $0.00 for Q2, exceeding market expectations of a 10-cent loss, indicating a significant improvement in the company's profitability.
Sales Growth: The company achieved sales of $79.4 million, surpassing the market forecast of $76.3 million, demonstrating strong product demand and driving overall performance enhancement.
Positive Market Reaction: Following the earnings release, AngioDynamics' stock received favorable attention from investors, reflecting confidence in its future growth potential, which may further drive stock price appreciation.
Optimistic Industry Outlook: With the recovery of the medical device sector, AngioDynamics' robust performance could attract more investor interest, strengthening its position in a competitive market.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

Sign up now to unlock expert insights and stay one step ahead of the market trends.

ANGO

$9.8+Infinity%1D

Analyst Views on ANGO

Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 10.010

Low

16.00

Averages

19.33

High

24.00

Current: 10.010

Low

16.00

Averages

19.33

High

24.00

Canaccord

John Young

Buy

maintain

$15 -> $17

2025-07-16

Reason

Canaccord

John Young

Price Target

$15 -> $17

AI Analysis

2025-07-16

maintain

Buy

Reason

Canaccord analyst John Young raised the firm's price target on AngioDynamics to $17 from $15 and keeps a Buy rating on the shares. The firm said the company had another well-executed quarter, driven by growth in its Med-Tech business with nice beats across the board. Med-Tech, Med-Device, total revenues, adj. EBITDA and adj. EPS all beat estimates, capping off a momentum-building year for the company and there wasn't much thesis changing news for the company during the quarter.

Lake Street

Buy

initiated

$24

2025-07-16

Reason

Lake Street

Price Target

$24

2025-07-16

initiated

Buy

Reason

Lake Street initiated coverage of AngioDynamics with a Buy rating and $24 price target. The firm says the company has transformed its portfolio into faster-growth and higher-margin cardiovascular and cancer treatment products. The Street is missing AngioDynamics' strategic realignment as the shares should be valued more in line with higher multiple medical technology companies, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANGO

Unlock Now

About ANGO

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.